ACR GUIDELINES Bundle (free trial)

ACR Rheumatoid Arthritis RA Guidelines

American College of Rheumatology GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/622897

Contents of this Issue

Navigation

Page 10 of 19

9 c Treatment target should ideally be low disease activity or remission. d Tapering denotes scaling back therapy (reducing dose or dosing frequency), not discontinuing it and, if done, must be conducted slowly and carefully. Non-TNF biologic +/- MTX or TNFi +/- MTX Treat to Target c Another Non-TNF biologic +/- MTX Moderate or High Disease Activity a, b Another Non- TNF biologic +/- MTX or Tofacitinib +/- MTX Non-TNF biologic +/- MTX or Tofacitinib +/- MTX TNFi +/- MTX (in TNFi naïve) or Tofacitinib +/- MTX Do not discontinue all RA treatments d Moderate or High Disease Activity a, b Multiple TNFi failure Dual Failure: TNFi and Non- TNF biologic failure Multiple Non- TNF biologic failure Single Non- TNF biologic failure Single TNFi failure Moderate or High Disease Activity a, b

Articles in this issue

Archives of this issue

view archives of ACR GUIDELINES Bundle (free trial) - ACR Rheumatoid Arthritis RA Guidelines